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Summary
The efficacy of triple drug therapy for HIV-1 infection encourages its early use to prevent
damage to the immune system. We monitored the effects of such therapy on 12 patients with
14–75-mo histories of minimal disease, i.e., CD41 counts constantly .500/ml and little or no
lymph node enlargement. In this way, we could first determine the extent of viral replication
and immunoarchitectural changes in unenlarged nodes early in disease, and second follow the
response to triple therapy in plasma and lymphoid tissue in tandem. As is known for lymph
nodes with more advanced disease, the germinal centers showed productively infected T cells,
i.e., CD41CD1a2CD682 cells labeling intensely for HIV-1 RNA after in situ hybridization.
The unenlarged nodes also showed extensive HIV-1 RNA retention on a well-preserved, follicular dendritic cell (FDC) network, and the follicles were abnormal. There were numerous
CD81 cells, many expressing TIA-1 granule antigen. Also, in contrast to normal follicles,
CD41 T cell proliferation was active, with marked increases in the number of cycling, Ki671CD41CD45R01 cells. After 28 d and 3 mo of therapy, productively infected T cells decreased dramatically and often were not apparent. The labeling of the FDC network for viral
RNA also decreased, but not for gag protein. We conclude that HIV-1 replicates and accumulates in lymphoid organs before damage of the immune system, that at this stage of disease de
novo production of T cells occurs in the lymphoid tissue, and that the infection is sensitive to
triple drug therapy in both plasma and lymph nodes.

R

ecent developments in antiretroviral therapy have led
to substantial advances in the management of patients
infected with human immunodeficiency virus type 1
(HIV-1). The combination of two nucleoside analogues,
e.g., zidovudine (AZT), didanosine (ddl) or zalcitabine
(ddC), and an HIV-1 protease inhibitor (triple drug therapy) typically yields a dramatic reduction of HIV-1 RNA
in the plasma and a significant increase in CD41 T cells in
the peripheral blood (1, 2). It is now important to assess
therapeutic responses in the tissues and not just viral loads
and CD41 lymphocytes in the blood. It is well established
that HIV-1 particles, gag proteins, and viral RNA are re949

tained on the surface of follicular dendritic cells (FDCs)1 in
germinal centers (GCs) (for review see reference 3). By in
situ hybridization with HIV-1 RNA probes, productively
infected cells are also numerous, particularly in the GCs (4–
11). Treatment strategies should therefore reduce these
large depots of viral RNA and infected cells in the lymphoid tissue. Indeed, Cavert et al. have recently docu1Abbreviations used in this paper: APAAP, alkaline phosphatase anti–alkaline
phosphatase; ELT, extrafollicular lymphoid tissue; FDC, follicular dendritic cell; GC, germinal center; PGL, persistent generalized lymphadenopathy; SSC, standard saline citrate.
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mented a marked decrease in viral RNA in tonsil biopsies
from patients with advanced disease who were treated with
combination antiretroviral drugs (12).
A favorable therapeutic response also should restore the
architecture of the lymphoid tissue that is severely altered
during HIV-1 infection (for review see reference 13). Follicular hyperplasia usually is observed in patients with persistent generalized lymphadenopathy (PGL). This is associated with varying degrees of FDC damage and a marked
elevation of CD81 lymphocytes in both the T-dependent
zone and the GCs, the latter being an unusual site for
CD81 T cells. However, there has been little work on
lymph node architecture and viral burden in patients with
high CD41 T cell counts and no PGL.
The use of combination therapy early in disease holds
the potential of preventing virus-induced damage to the
immune system. Therefore, we initiated triple drug therapy
in infected seropositive asymptomatic patients with CD41
counts constantly .500/mm3. Most of the individuals
lacked lymphadenopathy. The goal of this study, therefore,
was twofold. First we sought information on histology and
viral replication in nonenlarged lymph nodes, given that
earlier data was obtained from patients with PGL. Second,
we wanted to assess the effects of triple drug therapy on
lymph node HIV-1 RNA and p24, as well as immunoarchitectural restoration of lymphoid tissue.
Materials and Methods
Patients. 12 volunteers were enrolled. Eligibility criteria
were: laboratory documentation of HIV-1 infection, CD41 T
cell counts constantly .500 cells/ml, no history of AIDS-defining
events, no prior antiretroviral therapy, and .18 yr old. All patients
gave written consent to participate. The study was approved by
the local ethics committee (Arztekammer, Hamburg, Germany).
Important clinical data are summarized on Table 1. There were

Table 1.

two groups: eight patients who had no evidence of lymphadenopathy (group A) and four who had at least two peripheral lymph
nodes .3 cm (group B). Biopsies of axillary lymph nodes (group
A) or an enlarged node (group B) were done under local anesthesia within 7 d before beginning therapy. All patients received 250
mg zidovudine t.i.d., 0.75 mg zalcitabine t.i.d, and 2,400 mg sanquinavir t.i.d. Plasma viremia and CD41 T cell counts were determined at days 0, 3, 7, 10, and 14, and weekly thereafter. The
second lymph node biopsy was performed either 28 d (group A)
or 3 mo (group B and patient No. 8 from group A) of treatment.
Light microscopy. Tissues were fixed in 4% neutral-buffered
formalin overnight, embedded in paraffin, and stained with hematoxylin and eosin, Giemsa, or Gomori silver impregnation for
routine histology. Portions of lymph nodes were embedded in
tissue freezing medium (Leica Instruments, Nussloch, Germany),
snap frozen in liquid nitrogen, and stored at 2708C until use. As
controls, 10 lymph nodes with follicular hyperplasia not related to
HIV infection were selected from our files.
Immunohistochemistry. Dewaxed paraffin sections were placed
in a domestic pressure cooker containing 0.01 M buffered sodium
citrate solution (pH 6), boiled for 2 min, and chilled to room
temperature (14). Cryostat sections were fixed in 2% paraformaldehyde for 10 min. The sections were incubated with the primary antibodies (Table 2) according to the manufacturers’ instructions. Binding of antibodies was visualized by the alkaline
phosphatase anti–alkaline phosphatase (APAAP) technique using
New Fuchsin as chromogen. The sections were either counterstained with hematoxylin and mounted, or dehydrated through
graded ethanols and subjected to in situ hybridization to detect
HIV RNA.
Immunohistochemical Double Labeling. Proliferating CD41 T
cells or CD81 lymphocytes, and the TIA-11 CD81 T cell subset,
were detected on paraffin sections. After heat-mediated, antigen
retrieval in a pressure cooker, the sections were incubated with
anti-CD4 or -CD8 mAbs at 48C overnight. Binding of antibodies
was detected either with biotin-avidin peroxidase or with
APAAP using New Fuchsin as red chromogen. The sections
were then heat treated again for 5 min and incubated either with
antibody MIB-1 to the proliferation antigen Ki-67 (15), or with

Patient Characteristics at Baseline

Patient
No.

Gender

Age

HIV1

CD41

CD4/CD8
ratio

Virus load
RNA

PGL

Second
bx

1
2
3
4
5
6
7
8
9
10
11
12

Male
Male
Male
Male
Female
Male
Female
Male
Male
Male
Male
Male

51
27
32
27
30
39
46
27
56
27
35
39

mo
75
39
60
28
67
69
43
28
14
15
52
75

cells/ml
540
580
510
610
1,350
560
570
670
380
570
560
560

0.24
0.65
0.75
0.86
0.68
0.58
0.80
0.86
0.18
0.50
0.50
0.26

eq/ml
300,000
49,000
15,000
10,000
6,500
6,000
,500
,500
48,000
37,500
31,000
9,200

No
No
No
No
No
No
No
No
Yes
Yes
Yes
Yes

28 d
28 d
28 d
28 d
28 d
28 d
28 d
3 mo
3 mo
3 mo
3 mo
3 mo

950

HIV-1 Infection and T Cell Growth in Unenlarged Nymph Nodes

the TIA-1 mAb that reacts with killer cell granules (16) overnight
at 48C. The second antibody was visualized with APAAP and
Fast Blue salt.
Immunofluorescence Studies. The association of HIV p24 with
FDCs and T cells was analyzed on frozen sections by two-color
immunofluorescence beginning with FITC-antibodies to CD23
(FDCs), CD4, or CD8. This was followed with an unlabeled antibody to p24, CD25, or CD45R0, and TRITC-goat anti–
mouse Ig.
Detection of HIV RNA in Lymph Nodes. An 35S-labeled, single-stranded, antisense RNA probe (Lofstrand Labs., Gaithersburg, MD) was used. The probe contained 1.4–2.7-kb fragments
collectively representing z90% of the HIV-1 genome (8). The
hybridization was done on paraffin and frozen sections, the latter
being fixed in 4% paraformaldehyde for 20 min before hybridization. To increase the diffusion of the probe, paraffin sections were
treated either with proteinase K (0.01 mg/ml) for 8 min at room
temperature or were placed in a domestic pressure cooker containing citrate buffer and heated for 5 min. The pairs of sections
were processed at the same time. The sections were placed in a
cocktail (50% formamide, 0.5 M NaCl, 10 mM Tris HCl, pH
7.4, 1 mM EDTA, 0.02% Ficoll-polyvinylpyrrolidone-BSA, and
7 mg of tRNA/ml) and prehybridized for 2 h at 458C. The sections were covered with a hybridization mixture (prehybridization cocktail, 10% dextran sulfate, and 2 3 106 dpm of probe/ml)
and incubated in a 458C moist chamber overnight. The sections
were washed for 15 min with three changes, each in 50% formamide: 50% 23 standard saline citrate (SSC), 23 SSC–0.1% Tri-

Table 2.

ton, and finally 0.13 SSC. Sections were digested with RNase
(Boehringer Mannheim GmbH, Mannheim, Germany) at 378C
for 40 min, washed again in 23 SSC, and dehydrated in 0.3 M
ammonium acetate with 70–90% ethanol. The slides were dipped
into emulsion (NTB2; Kodak, Rochester, NY). After 7 d of exposure at 48C, the slides were developed in developer (D19;
Kodak), fixed, counterstained with hemalaun, and mounted. As a
positive control, cytospin preparations of H9 cells infected with
HIV-1 were hybridized with the same probe. As a negative control, sections were hybridized with a radiolabeled sense-strand
probe. The sections were examined with a microscope (Axiophot; Carl Zeiss Inc., Jena, Germany) equipped with epiluminescent illumination. Cells were considered positive for viral gene
expression if the grain count was more than six times the highest
background.
Semiquantitative Image Analysis of HIV RNA. To examine the
extent and density of diffuse HIV RNA signals in the GCs, we
used a microscope (Axioskop; Carl Zeiss Inc.) equipped with
Plan Neofluar for transmitted and incident light, a 3CD color
camera, and a PC-based image analysis system (KS 400; Kontron,
Esching, Germany). In the first step, the transmission light image
of the lymph node sections was digitalized and stored. An incident light image showing the reflectance of the silver grains was
then obtained. Subsequently, these two images were superimposed. The area occupied by silver grains (RNA) was expressed as
a percentage value of total GC area.
Semiquantitative Image Analysis of Proliferating CD4 or CD8 T
Cells. Using a 340 objective, regions of GCs and T zones were

Antibodies Used in This Study
Dilution

Antibody CD
(clone)

Main specificities
in lymphoid tissue

CD1a (010)
CD1a (Leu 6)
CD4 (NCL-CD4-1F8)
CD8 (C8/144B)
CD20 (L26)
CD23
CD57 (Leu 7)
CD68 (KP1)
CD45R0 (UCHL-1)
CD25
anti-p24
MIB-1
Ki-M4p
TIA-1

Subset of DC and T
Subset of DC and T
T helper, DC, mac
T cytotoxic
B cells
Fce receptor II
NK subset, T subset
macrophages, some DCs
activated, memory cells
b chain of IL-2 receptor
p24 protein of HIV-1
Ki-67 cell cycle
FDC
15-kD protein in
cytotoxic cells
EBV induced; DC
Subset of DCs

p55
S-100 (15E2E2)

Paraffin

Frozen

Source

Undiluted
ND
1:40
1:10
1:50
1:50
1:10
1:10
1:100
ND
1:5
1:10
1:50
1:500

ND
1:10
1:50
1:40
1:50
1:100
1:10
1:50
1:200
1:5
1:10
1:20
1:100
ND

Immunotech*
Becton Dickinson
Novocastra
Dakopatts
Dakopatts
Dakopatts
Becton Dickinson
Dakopatts
Dakopatts
Becton Dickinson
Dakopatts
Dianova
M. Parwaresch‡
Coulter

1:5
1:100

1:5
ND

E. Langhoff
Boehringer
Mannheim

* Immunotech, Marseille, France; Becton Dickinson, Mountain View, CA; Novocastra, Newcastle upon Tyne, UK; Dakopatts, Copenhagen, Denmark; Dianova, Hamburg, Germany; Coulter Corp., Krefeld, Germany; Boehringer Mannheim GmbH, Mannheim, Germany.
‡ M. Parwaresch, University of Kiel, Kiel, Germany; E. Langhoff, University of Hershey, Hershey, PA.
DC, dendritic cell.
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marked on the monitor. Total CD41 or CD81 cells, and double
positive cells (CD4/Ki-67 or CD8/Ki-67), were counted. Ten
fields of GCs and T zones were counted on each slide. The percentage of a T cell subset expressing MIB-1 was calculated in the
designated areas.
Assay for Detection of HIV-1 RNA in Plasma. Plasma aliquots
were stored at 2708C. HIV-1 RNA was measured using PCR
(Amplicor Monitor HIV-1; Hoffmann-La Roche, Basel, Switzerland) according to the manufacturer’s instructions (17). The limit
of detection of this assay is 200 RNA copies/ml. When levels below this cutoff were found, an ultrasensitive version (20 copies/ml)
of this assay was performed.

Results
Technical Considerations of HIV RNA Detection. To allow for the penetration of probes into paraffin sections, tissue permeabilization is usually necessary. Current protocols
recommend pretreatment with HCl and digitonin and/or
proteinase K (8, 18). However, we find that these agents
damage the morphology, making the evaluation of pathologic changes difficult. Furthermore, recently available antibodies that detect CD41 or CD81 T cells in paraffin sections (Table 2) do not react if the sections are treated with
proteolytic enzymes but instead require superheating before immunostaining. Since high temperature also denatures RNA, yielding unfolded linear forms to which probes
hybridize efficiently, we reasoned that boiling of tissue sections might intensify both RNA hybridization and immu-

nostaining with new mAbs while preserving morphology.
In pilot experiments, sections were boiled in a domestic
pressure cooker for 5 min (14). Companion sections were
pretreated with 0.2 N HCl for 30 min followed by proteinase K in various concentrations (5–20 mg/ml) at 378C or at
room temperature for 8–15 min, and hybridized according
to published protocols (8, 18). Sections were exposed at
48C for 1, 3, 4, 5, 7, and 10 d to optimize autoradiographic
signals.
Treatment of sections with high temperature substantially increased the number (50–70%) and grain counts of
actively infected or “hot” cells (cells labeling heavily with
antisense RNA probe) over prior reports (3–12, 18, 19;
Fig. 1, right, arrows). However, protein digestion facilitated
the access of the probe to FDC-bound HIV that is complexed with antibodies, giving increased diffuse FDC labeling (8, 20; Fig. 1, left, arrow). We confirmed the findings of
Cavert et al. (12) that longer autoradiographic exposure
times increased the sensitivity of in situ hybridization in
both approaches. For example, a 1-d exposure (recommended to quantitate FDC-bound HIV RNA; reference
18) gave low grain counts and low frequencies of productively infected cells, but exposure times of 5–7 d increased
the numbers of hot profiles and FDC-bound HIV RNA.
Further lengthening of exposure times did not increase sensitivity and led to a reduction of signal/noise ratio.
Because high temperature treatment provided for (a) immunohistochemical detection of important antigens, (b) ef-

Figure 1. Methodological aspects of HIV-1 RNA detection. Adjacent lymph node sections were treated by boiling in a pressure cooker (right) or with
proteinase K (left), and then hybridized with radiolabeled antisense RNA probes. The autoradiograms were photographed under bright field microscopy.
The boiled sections contained more numerous, discretely labeled, productively infected or hot cells (arrows, right), and tissue preservation was better. Proteinase K–treated sections, in contrast, exhibited a more heavily labeled FDC network of RNA (arrow, left).
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Figure 2. Direct relationship between the number of productively infected cells in lymph node sections and the level of plasma RNA (correlation coefficient: 0.65). The data are mean numbers of hot GC cells per
lymph node section.

ficient RNA hybridization signals with low background
noise, and (c) well-preserved morphology, we used this
method to monitor the structure of lymphoid organs and
the numbers of HIV-1–producing cells. Digestion with
proteinase K of additional sections was used to analyze
FDC-bound HIV RNA. The high density of hybridization
signals over single cells and the FDC network did not permit counting of the silver grains, so HIV-1 copy numbers
were not calculated in the manner that was described previously (12, 18). Instead, therapy-induced changes were
monitored semiquantitatively in terms of the area of GCs
occupied by diffusely distributed silver grains and expressed
as the percentage of total GC area. HIV RNA1 cells were
counted over the entire section, and their localizations
were noted. Since labeled cells localized preferentially to B
cell follicles (Fig. 1), we used the term extrafollicular lymphoid tissue (ELT) for all nonfollicular regions, omitting
further distinction of T-dependent zones, interfollicular areas, medulla, and sinuses.
Detection of HIV RNA in Lymph Nodes at the Baseline.
Even though most of the lymph nodes were not enlarged,
we still observed viral RNA in all. As in enlarged nodes (3–
12, 18, 19), there were two patterns of hybridization signals: diffuse labeling over the FDC network in the light
zones of GCs, and strong localized labeling of single cells,
usually in GCs and the mantle zone (Fig. 1). Plasma RNA
levels correlated directly with the frequency of hot HIVinfected cells in the lymph nodes (Fig. 2). The area of GCs
occupied with FDC-associated RNA varied about twofold
over the range of plasma RNA levels in our patient cohort
(see Table 4).
Two patients had very low plasma RNA levels of ,500
copies/ml before treatment. Patient No. 8 showed only a
few infected cells in the ELT but no diffuse labeling over
FDCs, which were present. Patient No. 7 had a diffuse hybridization signal over 15–30% of the GCs, with productively infected cells mainly in ELT (up to 10 cells/cutting
level) and rarely in GCs (up to 3/cutting level). We con953
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clude that normal-sized nodes from patients with CD4
counts of .500/ml and low levels of plasma RNA show
clear productively infected cells and viral RNA accumulation.
Light Microscopy and Lymphocyte Subsets in the Lymph
Nodes before Therapy. The classical microanatomy of the
lymph nodes, i.e., the cortex, the paracortex, the medulla,
and the sinuses were well preserved and showed histologic
alterations commonly seen in viral lymphadenitis. The sinus system was slightly dilated and contained many lymphocytes, macrophages, and not seldomly, neutrophils. The
T-dependent zones, identified by the presence of high endothelial venules and interdigitating dendritic cells (S-1001
and p551), were well developed with increased high endothelial venules and many CD31 T and CD201 B blasts.
Increased numbers of plasma cells and macrophages were
also seen in the interfollicular regions.
The histology of the GC differed in the two groups.
Only the enlarged lymph nodes from group B patients had
the previously described, HIV-1–associated, follicular hyperplasia. The follicles, located both in the cortex and more
diffusely, were enlarged (.700-mm diam) and irregularly
shaped, with serrated or protruding margins, sometimes becoming confluent. Attenuation of the mantle zone was evident in some follicles. The GCs showed clear zonation.
The light zone had centrocytes, CD41 T cells, and some
plasma cells. The dark zone contained many centroblasts (B
blasts) and tingible body macrophages. In group A patients
with unenlarged nodes, follicular size was normal, 300–450
mm diam (21). The follicles were usually round and the
GCs showed zonation with only slightly extended dark
zones. As in follicular hyperplasia, the follicles had a cortical
and diffuse distribution occupying 17–24% of the lymph
node cross-sectional area.
The numbers of CD41 T cells both in the follicles and
T-dependent zones were in the same range as that seen in
non-HIV–infected, control lymph nodes (Fig. 3 a; Table
3). As in follicular hyperplasia not attributed to HIV infection, .95% of the CD41 cells in the GCs were CD45RO1
and z40–60% also expressed CD57. The proportion of
CD41CD45RO1 cells (41–63%) in the T-dependent
zones did not differ significantly from control nodes. The
number of CD41CD251 activated T cells showed a wide
range of variation (1.4–15.1%) within the same section, but
in HIV-infected patients more CD41 lymphocytes in the
GCs expressed this activation marker than in the controls.
As reported in HIV-12 lymph nodes (22, 23), no CD251
cells were found among the intrafollicular, CD571CD41
cells.
Abnormalities in the Follicles of Unenlarged HIV-1–infected
Lymph Nodes. In HIV-1 infection, continuous virus replication results in a loss of CD41 lymphocytes with z109
CD41 T cells being destroyed each day (24). In our patients, the levels of CD41 T cells were in the normal range,
both in the circulation and in the lymph node, in spite of
the fact that infection was acquired 1–6 yr earlier. Therefore, we determined the growth fraction of the CD41 cells
to see if peripheral T cell numbers might be maintained in
the nodes. In agreement with published data (25), we found

Figure 3. Architecture and immunolabeling of infected lymph nodes. (a) CD41 T cells (red) were abundant in the T cell area (T), but were also found
in the B cell follicle, as is typical of normal lymph nodes. (b) However, in HIV-1 infection, CD41 T cells (red) showed an increase in the extent of labeling for Ki-67 (blue; arrows, double positive cells). (c) In HIV-1 infection, CD81 T cells (brown, arrow) were abundant in GCs (B) that were full of Ki-671
B blasts (blue). (d) The FDC network (arrows) was visualized with the Ki-Mp4 monoclonal antibody.

Figure 4. Effect of triple drug therapy on lymph node HIV-1 RNA. (a and b) The in situ hybridization signal for viral RNA in the FDC network is
shown by reflected light (turquoise, arrow) before (a) and after (b) 28 d of therapy. (c and d) The immunolabeling signal for viral p24 or gag protein in the
FDC network is shown (red) together with the in situ hybridization for viral RNA (turquoise). Before therapy (c), the red p24 (arrow) was obscured by the
silver grains over viral RNA. After therapy (d), p24 persisted and was readily visible because the viral RNA signal was so weak.
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Table 3.

Percentage of T Cell Subsets in Lymph Nodes of HIV1 Patients and HIV2 Controls
Controls, HIV2

T cell
subsets
CD41Ki-671
CD81Ki-671

Group B, HIV1

GC

T zone

GC

T zone

GC

T zone

1.4 6 0.4
(0–3)
ND

2.6 6 0.6
(0.4–4.6)
2.9 6 0.3
(1.5–3.9)
43 6 6.5
(38–51)
25 6 2.2
(19–32)
49 6 5.0
(36–58)
3.7
(2.5–5.8)

19 6 2.0
(8–31)
0.6 6 0.1
(0.2–0.8)
.95

3.9 6 0.5
(0.9–5.4)
5.7 6 0.4
(2.7–7.0)
50 6 3.7
(41–63)
65 6 5.3
(57–72)
73 6 3.5
(61–79)
1.3
(0.9–2.0)

18 6 1.7
(9.8–28)
1.0 6 0.2
(0.4–1.9)
.95

3.4 6 0.7
(1.3–5.0)
5.1 6 1.0
(2.0–6.0)
43 6 2.8
(34–57)
69.0 6 3.3
(60.0–72.8)
75 6 1.4
(60–81)
1.5
(1.0–2.5)

CD41CD45R01

.95

CD81CD45R01

ND

CD81TIA-11

ND

CD4/CD8 ratio

Group A, HIV1

20
(14–31)

.95
.95
1.6
(1.0–2.4)

.95
.95
1.8
(1.0–2.7)

*Values are 6 SE based on 10 fields of T-dependent zone/lymph node and on 8 GCs/lymph node. Range is shown in parenthesis.
ND, not determined because of too few CD81 T cells.

that intrafollicular T cells in noninfected patients usually
were not proliferating, i.e., 0–3% expressed the Ki-67 cell
cycle antigen (Table 3). This contrasted to our group A and
B lymph nodes in which 8–31% of the CD41 cells in GCs
expressed Ki-67 (Fig. 3 b; Table 3). In the T-dependent
zone, the differences in proliferation index between controls and infected lymph nodes were less pronounced (0.9–
5.4 versus 0.4–4.6% in the control lymph nodes). In contrast to CD41 lymphocytes, CD81 T cells proliferated
mainly in the ELT. In the T-dependent zone, 2.7–7.0% of
the CD81 cells were cycling, but in the GC, only 0.2–
0.8% of the CD81 cells were Ki-671.
In all infected patients, the numbers of CD81 lymphocytes were markedly elevated both in the follicles and the
ELT (Fig. 3 c). This led to markedly decreased CD4/CD8
ratios in the T-dependent zone (1.3 versus 3.7 in uninfected controls) and in the GC (1.6 versus 19.8 in controls).
Within GCs, CD81 cells were almost uniformly CD45RO1
(.95%), whereas in the T zone, 57–72% of CD81 cells belonged to this memory subtype. Up to two thirds of CD81
cells in the T-dependent zone, and nearly all CD81 T cells
in the GCs, contained TIA-11 cytotoxic granules. Thus, in
follicles and in T zones, the proportion of CD81 T cell
subsets was similar to that seen in persistent generalized
lymphadenopathy (26, 27)
The Ki-M4p mAb to FDCs showed that the FDC network was largely confined to the light zone of the infected
GCs (Fig. 3 d). Even though CD81TIA1 T cells had invaded the follicles, no evidence of significant damage to the
FDC network was apparent. The CD23 antigen on FDC
was upregulated. The band of CD231 FDCs was expanded
into the basal light zone and, in patients with plasma viremia .50,000 copies/ml, into the neighboring regions of
the dark zone. Double labeling revealed that immune com955

Racz et al.

plexes of HIV-1 p24 antigen were bound only on the
CD231 portion of the FDC network.
Phenotype of HIV RNA1 Cells. In situ hybridization
and immunohistochemistry together revealed that CD41
lymphocytes expressed viral RNA both in the GCs and
ELT (not shown). Exclusively CD45RO1 memory type,
CD41 T cells replicated HIV-1. Viral RNA was not detected in the CD571 subset that resides in the GCs. Only a
minority of cells with HIV gene transcripts expressed
CD25. We were not able to detect CD681 macrophages or
CD1a1 dendritic cells with viral RNA. The diffuse RNA
labeling was found on the CD231-activated part of the
FDC network.
Viral RNA and Immunohistologic Changes in Lymph Nodes
of Treated Patients. Triple drug therapy markedly reduced
HIV-1 RNA in the plasma of all patients, and in the lymph
nodes of all but one at day 28 (Table 3). Three patients
(baseline viral load of 300,000, 6,500, and 500 copies/ml)
had no detectable productively infected cells. Thus, a major
reduction in virus-producing cells was not dependent on
the virus load in the plasma or the number of HIV RNA1
cells in lymph nodes at the baseline. In all other patients
treated for 28 d, a few HIV-1 RNA1 cells could still be detected in the GCs (up to three per section) and in the ELT
(up to four per section). Phenotyping of the residual hot
cells after treatment revealed no change to a nonlymphoid
phenotype. The extent (Fig. 4, a and b; Table 4) and density of diffuse FDC labeling in GCs also showed a marked
reduction after 28 d of treatment.
In patients treated for 3 mo, we could not detect hot
productively infected cells in either paraffin or cryostat sections. FDC-bound HIV RNA remained decreased in all
cases. Surprisingly, GCs did not react uniformly. 34–78%
of GCs contained no hybridization signals at 20 cutting

Table 4.

Patient Features before and after Triple Drug Therapy
CD41 cell counts

Patient
No.
Bx

Baseline

Plasma RNA values

At second
bx

‡ At

*Baseline

cells/ml
1
2
3
4
5
6
7
8
9
10
11
12

540
580
510
560
1,320
560
570
1,080
380
570
560
560

second
bx

copies/ml
300,000
,20
49,000
630
15,000
645
10,000
,20
6,500
113
6,000
45
,500
,20
,500
,20
48,000
,20
37,500
,20
31,000
,20
9,200
,20

490
570
720
600
1,110
1,000
720
1,170
540
500
680
550

RNA1 cells in GC

RNA1 cells in ELT
(mean)

Diffuse RNA:
percent of GC area

Baseline

At second
bx

Baseline

At second
bx

Baseline

At second
bx

33
63
28
11
0
4
3
No GCs
19
22
37
13

0
2
15
0
0
0
0
No GCs
0
0
0
0

22
31
22
4
5
8
10
4
12
9
14
7

0
2
17
0
0
0
0
0
0
0
0
0

42.0
37.1
16.7
31.0
17.2
8.3
14.7
No GCs
27.6
15.6
23.0
17.5

7.2
2.9
28.5
1.4
1.5
4.7
7.6
No GCs
0.7§
2.1i
3.4i
2.7i

*Conventional PCR.
‡ Ultrasensitive PCR.
§ One GC with 12.8%.
i Three or more GCs with 7–10.2%.

levels, but in some follicles, up to 12.5% of the GC was occupied by HIV RNA with a low intensity of hybridization.
Unexpectedly, FDC-bound HIV-1 p24 was not overtly reduced after triple drug treatment (Fig. 4, c and d). Immunohistochemical and histologic changes at the baseline, e.g.,
follicular hyperplasia, increased CD81 cells, high T cell
proliferation rates, were not changed by therapy.
Discussion
Active HIV-1 Accumulation in Unenlarged Lymph Nodes
from Patients with Minimal Disease. New therapies against
HIV-1 require assessment of their impact on viral loads in
lymphoid tissue. Sensitive tools are now available to quantify HIV RNA in plasma, but lymphoid tissues contain the
major depots of virus (3–12, 18, 19). In this study, we emphasized in situ hybridization of lymph node sections to
detect both productively infected cells as well as immune
complexes of virus on FDCs. We found that viral infection
was active in the unenlarged lymph nodes of asymptomatic
patients with CD41 counts .500/ml.
The GCs of untreated patients contained p24 gag protein and HIV-1 RNA bound to FDCs. HIV trapping occurred exclusively in the light zone where the FDC network was activated and CD231. This part of the FDC
network can be missed or overrepresented in a GC, depending upon the plane of sectioning. This needs to be
taken into account when amounts of captured RNA are
estimated. By measuring the FDC-bound HIV RNA in
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GCs containing both light and dark zones, we found that
15–30% of the GCs in most lymph nodes was occupied by
RNA when the plasma viremia varied from 500–50,000
copies/ml.
Plasma HIV-1 RNA concentrations were much better
reflected by the number of actively infected cells in the
lymph nodes (Fig 2). In patients with plasma loads of ,500
copies/ml, only a few cells expressed HIV RNA and the
grain counts were low. With increasing plasma viremia, the
number of cells with HIV RNA per total area increased. In
patients with plasma viremia of .15,000 copies/ml, the
vast majority of hot cells had high grain counts, suggesting
high levels of viral replication in each.
It has been suggested that chronically infected macrophages, being more resistent to the cytopathic effect of HIV,
could be responsible for chronic virus production (28).
Therefore, we investigated the lineage of productively infected cells by double labeling the lymph node sections for
HIV-1 RNA and the CD68 macrophage marker or the
CD4 T cell marker. Exclusively, CD41 lymphocytes of the
CD45RO1 memory type, and not larger CD681 macrophages, produced HIV-1 RNA in the lymph nodes. It is
possible that b-chemokines (29, 30) decrease the replication of virus in macrophages in situ.
Morphology of HIV-1–infected Lymph Nodes from Patients
with High CD4 Counts and without Persistent Generalized
Lymphadenopathy. In spite of the excellent clinical status
of our patients (Table 1), even the nonenlarged lymph
nodes showed alterations that are seen in viral lymphadeni-
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tis. For unenlarged nodes (group A patients), the follicles
were normal in size, whereas enlarged nodes (group B patients) had follicular hyperplasia. In both groups, the follicles could be diffusely distributed rather than confined to
the outer cortex. The GC microenvironment was clearly
disturbed. For example, there were many infiltrating CD81
T cells, and the CD23 antigen was upregulated on the
FDC network. The FDC network was expanded in those
lymph nodes that had hyperplastic GCs, but no FDC damage was detectable. This is in contrast to more advanced
stages of disease in which a deterioration of the FDC network occurs consistently during the follicular hyperplasia
stage of PGL (for review see reference 31).
It is thought that HIV-1 within the GC is somehow responsible for FDC death. However, the lack of FDC loss in
our patients despite the presence of HIV-1 RNA, p24 protein, and a substantial history of infection (1–6 yr), suggests
that HIV-1 infection per se does not damage the FDCs.
Possibly it is a loss of CD41 T cells that underlies FDC
malfunction, and CD41 T cells were preserved in the patients that we studied here. FDC development in mice
with severe combined immunodeficiency mice requires
transfer of both B and T cells (32).
In many ways, the histologic changes that were seen in
unenlarged lymph nodes were similar to those reported
earlier for more extensive disease including generalized
lymphadenopathy. The major difference was in the extent
of follicular hyperplasia, which was minimal in the unenlarged lymph nodes. Since the follicles nevertheless harbored productively infected cells as well as FDC-bound
RNA and p24 of HIV-1, our observations suggest that host
factors rather than the virus itself or viral components deposited in the GC drive follicular hyperplasia.
Response to Triple Drug Therapy. Viral burdens in both
plasma and lymph nodes were markedly sensitive to triple
drug therapy, with a major effect being within 28 d of treatment. Most productively infected T cells in lymph nodes
had disappeared in 28 d and were undetectable by 3 mo.
There were some unexpected findings that require further study. The first relates to the FDC network of viral
RNA that was sensitive to therapy as described (12, 33).
The longevity of immune complexes on FDCs is substantial with half lives in mice of .1–2 mo. Yet we found
marked decreases of viral RNA on FDCs in just 28 d (Fig.

4, a and b). It will be important to assess RNA on FDCs after longer periods of therapy. A second surprise was that
HIV-1 p24 protein was retained for longer periods, even in
follicles (Fig. 4, c and d) in which HIV-1 RNA was undetectable after 3 mo of therapy. Because of a remarkable stability of the p24 core during the decay of HIV-1 (34), we
assume that in our patients the FDC-bound p24 antigen is
not virion associated. Third, there were clear differences in
the clearance of FDC-bound HIV RNA among GCs
within the same lymph node. If the lability of FDC-associated HIV RNA is determined by the equilibrium between
production and clearance of virus from the circulation as
suggested (12), the same magnitude of RNA decay in all
GCs was expected, since in all of our patients plasma viral
load was suppressed to undetectable levels. The apparent
variability in the viral reservoirs that we observed in different GCs mandates some caution in monitoring the efficacy
of therapy with fine-needle aspiration, or with tissues containing a limited number of GCs, e.g., tonsil and gut biopsies.
CD41 T Cell Proliferation with GCs of HIV-1–infected Individuals. Immune reconstitution is a vital aspect of therapy, and suppression of virus replication can be accompanied by increases in the number of circulating CD41 T
cells (1, 2, 24, 35–39). It has been suggested that the T cell
expansion is a reflection of cell proliferation (24, 36). In
contrast, Wolthers at al. (38) reported that cellular redistribution rather than de novo production of CD41 T cells accounts for the initial increase of memory T cells during
therapy. Our demonstration of high proliferation rates (labeling for the Ki-67 cell cycle antigen) in CD41 T cells in
lymph nodes compared with uninfected controls provides
direct evidence that an accelerated CD41 T cell turnover
does indeed occur in HIV-1 infection. The high proliferation rates occur in intrafollicular CD41/CD45RO1 lymphocytes (Fig. 3 b), whereas control GCs contain many
such lymphocytes but few in the cell cycle. Possibly the
proliferation of intrafollicular CD41 T cells at the baseline
and after treatment is driven by immune complexes of
HIV-1 p24 presented by FDCs or GC dendritic cells. In
mice, T cells in GCs do proliferate upon antigenic stimulation (40). Our findings reveal a peripheral regenerative capacity within GCs, and this may account for observed increases in CD41 T cell counts during triple drug therapy.
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